Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer

Abstract

Background/aim The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer. Materials and methods Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures. Results There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabine-cisplatin group (p = 0.001). Conclusion Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.

The Reallife Comparison of FOLFIRINOX vs Gemcitabine Platinum Combination as a First-Line Treatment in Patients with Pancreatic Carcinoma

“…In many retrospective studies in the literature, the amount of patients who can take the current regimens according to the doses defined in the phase studies has not been stated. [12][13][14][15] Fragile patient groups treated in clinical practice cannot be treated at the planned dose. In our study, patients in both treatment groups could use treatment agents at a dose average lower than the dose per cycle specified in Phase II-III trials.…”

The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Biological Evaluations

“…In the case of pancreatic cancer, which is currently the seventh most abundant form of cancer [ 3 ], the introduction of Folfirinox multidrug therapy (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin: see Figure 1 ) in 2011 has not provided satisfactory results related to the survival rate. Similarly, the evaluation of combined gemcitabine therapies with other chemotherapeutic agents, such as topoisomerase inhibitors (capecitabine, pemetrexed), tyrosine kinase inhibitors (erlotinib, irinotecan), platinum compounds (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), in turn, against pancreatic cancer evidenced a lack of beneficial effects [ 4 , 5 ].…”

“…Sci. 2024, 25, x FOR PEER REVIEW 2 of 26 chemotherapeutic agents, such as topoisomerase inhibitors (capecitabine, pemetrexed), tyrosine kinase inhibitors (erlotinib, irinotecan), platinum compounds (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), in turn, against pancreatic cancer evidenced a lack of beneficial effects [4,5]. One of the directions related to the improvement of anticancer therapies is to find the combination of drugs that act synergistically [6].…”

Simple predictors for the completion of scheduled gemcitabine‑cisplatin regimens based on real‑world urothelial cancer data

“…Gemcitabine plus cisplatin (GC) therapy is a chemotherapy frequently used to treat urothelial carcinoma, biliary tract cancer, pancreatic cancer ( 1 ) and germ cell tumors ( 2 ). Lately, immune-checkpoint inhibitors and an antibody-drug conjugate ( 3 ) were approved as next-generation urothelial carcinoma therapies.…”